Detalles de la búsqueda
1.
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
Invest New Drugs
; 36(4): 536-544, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29188469
2.
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Drug Metab Dispos
; 42(1): 182-92, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24194513
3.
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Invest New Drugs
; 31(4): 833-44, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23275061
4.
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
PLoS One
; 17(7): e0268244, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849586
5.
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.
Mol Cancer Ther
; 20(4): 641-654, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536188
6.
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Clin Cancer Res
; 25(23): 7175-7188, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31409612
7.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Mol Cancer Ther
; 18(12): 2207-2219, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530649
8.
Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29866156
9.
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Oncotarget
; 9(6): 6659-6677, 2018 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29467918
10.
Activating the Wnt/ß-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
PLoS One
; 10(4): e0125028, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25915038
11.
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Clin Cancer Res
; 20(23): 6059-70, 2014 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25231402
12.
Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles.
Bioanalysis
; 5(2): 159-70, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23330559
13.
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Clin Cancer Res
; 19(20): 5699-710, 2013 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23989980
14.
How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?
J Pharm Sci
; 101(5): 1932-40, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22344827
15.
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns.
Cancer Manag Res
; 1: 49-59, 2009 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21188123
16.
Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.
J Pharmacol Exp Ther
; 319(1): 293-8, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16803862
17.
Developmental expression of the major human hepatic CYP3A enzymes.
J Pharmacol Exp Ther
; 307(2): 573-82, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12975492
18.
Developmental expression of human hepatic CYP2C9 and CYP2C19.
J Pharmacol Exp Ther
; 308(3): 965-74, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14634042
Resultados
1 -
18
de 18
1
Próxima >
>>